CareLit · DOI-Nachweis · Pneumologie
Reduction in disease progression with nintedanib in the INPULSIS™ trials
DOI 10.1055/s-0035-1544832
Bibliografische Angaben
Nachweis in CareLit
Autor:innenM Kreuter, V Cottin, H Taniguchi, HR Collard, L Richeldi, S Stowasser, I Tschoepe, R Schlenker-Herceg, G Raghu
ZeitschriftPneumologie
Ausgabe02/2015
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: Nintedanib, an intracellular inhibitor of tyrosine kinases, is in development for the treatment of idiopathic pulmonary fibrosis (IPF). The INPULSIS™ trials were two replicate 52-week, randomized, double-blind, placebo-controlled Phase III trials that investigated the efficacy and safety of nintedanib 150 mg twice daily in 1066 patients with IPF. Declines in forced vital capacity (FVC) % predicted of > 5…
Zitieren
Zitierempfehlung
M Kreuter, V Cottin, H Taniguchi, HR Collard, L Richeldi, S Stowasser, I Tschoepe, R Schlenker-Herceg, G Raghu (2015) Reduction in disease progression with nintedanib in the INPULSIS™ trials. Pneumologie (02). https://doi.org/10.1055/s-0035-1544832
Mit CareLit weiterarbeiten